Merrill maintains ZymoGenetics at buy

ZymoGenetics, Inc. was maintained by Merrill Lynch analyst Hari Sambasivam at a buy rating after the company held an investor day and provided highlights for pipeline products, including recombinant human thrombin (rhThrombin), which remains on track, and TACl-lg, which is on schedule to provide phase 1 data for rheumatoid arthritis and systemic lupus erythematosus. Shares of the Seattle biotechnology company were down 4 cents, or 0.24%, at $16.52 on volume of 118,328 shares versus the three-month running average of 176,462 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.